Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elisabeth Clodi
Observed names:
Clodi, Elisabeth,
E. Clodi
Institution:
Octapharma (Austria)
Observed institution:
Octapharma (Austria)
OpenAlex ID:
A5044710211
Trial of Intravenous Immune Globulin in Dermatomyositis
2022
·
Rohit Aggarwal
, Christina Charles-Schoeman
, et al.
·
New England Journal of Medicine
·
268
PDF
Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy
2021
·
David R Cornblath
, Pieter A van Doorn
, et al.
·
Brain
·
54
PDF
Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study
2024
·
Rohit Aggarwal
, Joachim Schessl
, et al.
·
Arthritis Research & Therapy
·
26
PDF
Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study
2025
·
Christina Charles-Schoeman
, Joachim Schessl
, et al.
·
Rheumatology
·
10
PDF
Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study
2025
·
Rohit Aggarwal
, Joachim Schessl
, et al.
·
Rheumatology and Therapy
·
7
PDF
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
2023
·
David R. Cornblath
, Pieter A. van Doorn
, et al.
·
Drug Safety
·
7
PDF
Op0008 a Randomized, Double-blind, Placebo-controlled Phase Iii Trial of Ivig 10% in Patients With Dermatomyositis. the Proderm Study: Results on Efficacy and Safety
2021
·
R. Aggarwal
, C. Charles-Schoeman
, et al.
·
Annals of the Rheumatic Diseases
·
6
PDF
Treatment of Children with Primary Immunodeficiencies with a Subcutaneous Immunoglobulin 16.5% (Cutaquig ® [Octanorm])
2021
·
Roger H Kobayashi
, Jose Fernando Mandujano
, et al.
·
Immunotherapy
·
6
The ProDERM study: Safety and Tolerability Results from randomized, double-blind, placebo-controlled Phase-III-Trial in Patients with Dermatomyositis. (P3-1.004)
2022
·
Rohit Aggarwal
, Christina Charles-Schoeman
, et al.
·
Neurology
·
2
Autoimmune Myopathies
2020
·
R. Aggarwal
, C. Charles-Schoeman
, et al.
·
Neuromuscular Disorders
·
2
Correction: Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub‑analysis of the ProDERM Study
2026
·
Rohit Aggarwal
, Joachim Schessl
, et al.
·
Rheumatology and Therapy
PDF
POS0273 EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN ON PULMONARY MANIFESTATIONS IN PATIENTS WITH DERMATOMYOSITIS: POST-HOC ANALYSIS OF THE ProDERM DATA
2025
·
R. Aggarwal
, J. Schessl
, et al.
·
Annals of the Rheumatic Diseases
Pulmonary Manifestations in Patients with Dermatomyositis - Effect of IVIG Treatment: Data from the ProDERM Study (P3-11.011)
2025
·
Mazen Dimachkie
, Christina Charles-Schoeman
, et al.
·
Neurology
Evaluation of Autoantibody Status Effect on Dermatomyositis Patients’ Response to IVIG Treatment: Post-hoc Analysis of the ProDERM Trial (P4-14.007)
2024
·
Mazen Dimachkie
, Christina Charles-Schoeman
, et al.
·
Neurology
Pos1229 Do Myositis Autoantibodies Predict Response to Ivig in Dermatomyositis? a Post-hoc Analysis of the Proderm Trial
2023
·
C. Charles-Schoeman
, J. Schessl
, et al.
·
Annals of the Rheumatic Diseases
PDF
Safety of different IVIG doses for treatment of CIDP. The ProCID study (P3-1.003)
2022
·
Elisabeth Clodi
, Cornblath David
, et al.
·
Neurology
Show more works
View as search
Works count:
18
Citation count:
388
H-index:
6
I10-index:
4
Year
Topic
Type